JP2023554317A - 筋強直性ジストロフィー１を調節するための方法及び化合物 - Google Patents

筋強直性ジストロフィー１を調節するための方法及び化合物 Download PDF

Info

Publication number
JP2023554317A
JP2023554317A JP2023535364A JP2023535364A JP2023554317A JP 2023554317 A JP2023554317 A JP 2023554317A JP 2023535364 A JP2023535364 A JP 2023535364A JP 2023535364 A JP2023535364 A JP 2023535364A JP 2023554317 A JP2023554317 A JP 2023554317A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
pharmaceutically acceptable
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554317A5 (https=
Inventor
アンサリ，アシーム
ジェイ． ジェフリーズ，ショーン
シャー，プラティック
ジャン，チェンジ
Original Assignee
デザイン セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デザイン セラピューティクス，インク． filed Critical デザイン セラピューティクス，インク．
Publication of JP2023554317A publication Critical patent/JP2023554317A/ja
Publication of JP2023554317A5 publication Critical patent/JP2023554317A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Excavating Of Shafts Or Tunnels (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023535364A 2020-12-11 2021-12-11 筋強直性ジストロフィー１を調節するための方法及び化合物 Pending JP2023554317A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124592P 2020-12-11 2020-12-11
US63/124,592 2020-12-11
PCT/US2021/062974 WO2022126000A1 (en) 2020-12-11 2021-12-11 Methods and compounds for modulating myotonic dystrophy 1

Publications (2)

Publication Number Publication Date
JP2023554317A true JP2023554317A (ja) 2023-12-27
JP2023554317A5 JP2023554317A5 (https=) 2024-12-19

Family

ID=81974018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535364A Pending JP2023554317A (ja) 2020-12-11 2021-12-11 筋強直性ジストロフィー１を調節するための方法及び化合物

Country Status (7)

Country Link
US (1) US20240166693A1 (https=)
EP (1) EP4259133A4 (https=)
JP (1) JP2023554317A (https=)
CN (1) CN117279636A (https=)
AU (1) AU2021396454A1 (https=)
CA (1) CA3201756A1 (https=)
WO (1) WO2022126000A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024502469A (ja) * 2021-01-08 2024-01-19 デザイン セラピューティクス，インク． フリードライヒ運動失調症を治療するための方法及び化合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250120928A1 (en) * 2021-07-14 2025-04-17 University Of Maryland, Baltimore Suberoylanilide hydroxamic acid (saha) drugs, conjugates, and nanoparticles, and methods of use thereof
KR20250016096A (ko) * 2022-04-01 2025-02-03 디자인 테라퓨틱스, 인크. 헌팅턴병을 조절하기 위한 방법 및 화합물
US11976066B1 (en) 2023-10-23 2024-05-07 King Faisal University Substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates as anti-tubercular agents
GB202401731D0 (en) * 2024-02-08 2024-03-27 Univ Strathclyde Polyamides

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270727A1 (en) * 2005-05-03 2006-11-30 Christian Melander Small molecule therapeutics and uses therefor
WO2009060208A1 (en) * 2007-11-09 2009-05-14 Spirogen Limited Pyrrolobenzodiazepines
WO2010001933A1 (ja) * 2008-07-01 2010-01-07 学校法人日本大学 標的遺伝子特異的ヒストン修飾制御剤
JP2019199471A (ja) * 2018-05-14 2019-11-21 国立大学法人京都大学 配列選択的遺伝子活性制御剤
WO2019226835A1 (en) * 2018-05-22 2019-11-28 Design Therapeutics Inc. Methods and compounds for the treatment of genetic disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1260006A (zh) * 1996-02-26 2000-07-12 加利福尼亚州技术学院 双链dna和杂环低聚物之间复合物的形成
US6506906B1 (en) * 1996-02-26 2003-01-14 California Institute Of Technology Preparation and use of bifunctional molecules having DNA sequence binding specificity
US10517877B2 (en) * 2016-03-30 2019-12-31 Wisconsin Alumni Research Foundation Compounds and methods for modulating frataxin expression

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270727A1 (en) * 2005-05-03 2006-11-30 Christian Melander Small molecule therapeutics and uses therefor
WO2009060208A1 (en) * 2007-11-09 2009-05-14 Spirogen Limited Pyrrolobenzodiazepines
WO2010001933A1 (ja) * 2008-07-01 2010-01-07 学校法人日本大学 標的遺伝子特異的ヒストン修飾制御剤
JP2019199471A (ja) * 2018-05-14 2019-11-21 国立大学法人京都大学 配列選択的遺伝子活性制御剤
WO2019226835A1 (en) * 2018-05-22 2019-11-28 Design Therapeutics Inc. Methods and compounds for the treatment of genetic disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASAFUMI MINOSHIMA ET AL.: "Comparative analysis of DNA alkylation by conjugates between pyrrole-imidazole hairpin polyamides an", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 18, no. 3, JPN6025047604, February 2010 (2010-02-01), pages 1236 - 1243, ISSN: 0005734719 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024502469A (ja) * 2021-01-08 2024-01-19 デザイン セラピューティクス，インク． フリードライヒ運動失調症を治療するための方法及び化合物

Also Published As

Publication number Publication date
US20240166693A1 (en) 2024-05-23
WO2022126000A1 (en) 2022-06-16
CA3201756A1 (en) 2022-06-16
EP4259133A4 (en) 2024-11-27
EP4259133A1 (en) 2023-10-18
CN117279636A (zh) 2023-12-22
AU2021396454A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
JP2023554317A (ja) 筋強直性ジストロフィー１を調節するための方法及び化合物
CN114026083B (zh) 酪氨酸激酶的杂环抑制剂
CN109071552A (zh) 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法
KR20140072037A (ko) 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
US20240050576A1 (en) Methods and compounds for the treatment of genetic disease
KR20220072857A (ko) 질병 치료용 수용체 상호작용 단백질 키나아제 i 의 억제제
CA2990457A1 (en) Pyrrolidinyl and piperidinyl derivatives and pharmaceutical compositions thereof useful as gls1 inhibitors
AU2023205889A1 (en) Compounds and methods for treating friedreich's ataxia
JP2024502469A (ja) フリードライヒ運動失調症を治療するための方法及び化合物
KR20230080441A (ko) 전사 활성화 단백질의 이미다조피페라진 억제제
JP7777131B2 (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
EP4234550A2 (en) Methods and compounds for the treatment of genetic disease
HK40104905A (zh) 用於调节强直性肌营养不良1型的方法和化合物
HK40116639A (zh) 用於治疗弗里德希共济失调的化合物和方法
CN118695861A (zh) 用于治疗弗里德希共济失调的化合物和方法
HK40103182A (zh) 用於治疗弗里德希氏共济失调的方法和化合物
EA049760B1 (ru) Соединения и способы лечения атаксии фридрейха
HK40090030A (zh) 用於治疗遗传疾病的方法和化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212